Welcome to the Anticonvulsant Drug Development (ADD) Program
The Anticonvulsant Drug Development (ADD) Program is actively involved in the early identification and characterization of novel investigational anticonvulsant drugs for the symptomatic treatment of epilepsy. In addition, the research focus of the ADD Program is currently being expanded to include studies aimed at:
- Facilitating the identification and development of novel drugs for the treatment of therapy resistant epilepsy and other chronic central nervous system (CNS) disorders through applied research;
- Promoting a greater understanding of the pathophysiology of epilepsy and other CNS disorders through innovative basic research; and
- Stimulating future neuroscience research by providing a unique training environment for graduate and post-graduate students as well as clinical research fellows and visiting scientists.